Peripheral T-cell lymphomas: Initial features, natural history, and prognostic factors in a series of 174 patients diagnosed according to the REAL Classification

被引:211
作者
Lopez-Guillermo, A
Cid, J
Salar, A
Lopez, A
Montalban, C
Castrillo, JM
Gonzalez, M
Ribera, JM
Brunet, S
Garcia-Conde, J
de Sevilla, AF
Bosch, F
Montserrat, E
机构
[1] Hosp Clin Barcelona, Dept Hematol, E-08036 Barcelona, Spain
[2] Inst Catala Oncol, Barcelona, Spain
[3] Residencia Vall Hebron, Barcelona, Spain
[4] Hosp Univ Germans Trias & Pujol, Barcelona, Spain
[5] Hosp St Pau, Barcelona, Spain
[6] Hosp Ramon y Cajal, E-28034 Madrid, Spain
[7] Fdn Jimenez Diaz, E-28040 Madrid, Spain
[8] Hosp Clin, Salamanca, Spain
[9] Hosp Clin Univ, Valencia, Spain
关键词
peripheral T-cell lymphomas; prognosis;
D O I
10.1023/A:1008418727472
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Peripheral T-cell lymphomas (PTCL) account for about 10% of all lymphomas in Western countries. The aim of the present study is to analyze the initial characteristics and prognostic factors in a large series of PTCL patients. Patients and methods: 174 patients (105 male/69 female; median age 61 years) were diagnosed with PTCL according to the R.E.A.L. Classification in nine Spanish institutions between 1985 and 1996. Cutaneous lymphomas and T-cell chronic lymphocytic/prolymphocytic leukemia were excluded from the study. Univariate and multivariate analyses were used to assess the prognostic value of the main initial variables. Results: The distribution according to histology subgroup was: PTCL unspecified, 95 cases (54.4%); anaplastic large-cell Ki-1-positive (ALCL), 30 cases (17%); angioimmunoblastic T cell, 22 cases (13%); angiocentric, 14 cases (8%); intestinal T cell, 12 cases (7%), and hepatosplenic gamma delta T cell, one case (0.6%). As compared to the other types, ALCL presented more frequently in ambulatory performance status, without extranodal involvement, in early stage, normal serum beta 2-microglobulin (B2M) level and low-risk international prognostic index (IPI). Most patients were treated with adriamycin-containing regimens. The overall CR rate was 49% (69% for ALCL vs. 45% for other PTCL; P < 0.02). The risk of relapse was 48% at four years. Median survival of the series was 22 months (65 months for ALCL vs. 20 months for other PTCL; P = 0.03), with a four-year probability of survival of 38% (95% confidence intervals (95% CI): 28-48). In the univariate analysis, in addition to the histology, older age, poor performance status, presence of B-symptoms, extranodal involvement, bone marrow infiltration, advanced Ann Arbor stage, high serum LDH, high serum B2M, and intermediate- or high-risk IPI were related to poor survival. In the multivariate analysis the histologic subgroup (ALCL vs. other PTCL) (P = 0.02; response rate (RR): 4.3), the presence of B-symptoms (P = 0.02, RR: 2.2), and the IPI (low vs. high) (P = 0.04, RR: 2) maintained independent predictive value. When the analysis was restricted to the unspecified subtype, only IPI had independent prognostic value (P = 0.003; RR: 3.5). Conclusions: PTCL have adverse prognostic features at diagnosis, respond poorly to therapy and have short survival, with no sustained remission. ALCL constitutes a subgroup which responds better to therapy and has a longer survival.
引用
收藏
页码:849 / 855
页数:7
相关论文
共 42 条
[1]   Predictive capacity of the international prognostic factor index in patients with peripheral T-cell lymphoma [J].
Ansell, SM ;
Habermann, TM ;
Kurtin, PJ ;
Witzig, TE ;
Chen, MG ;
Li, CY ;
Inwards, DJ ;
Colgan, JP .
JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (06) :2296-2301
[2]  
ARMITAGE JO, 1989, CANCER, V63, P158, DOI 10.1002/1097-0142(19890101)63:1<158::AID-CNCR2820630125>3.0.CO
[3]  
2-B
[4]   Peripheral T-cell lymphomas. Clinico-pathologic study of 168 cases diagnosed according to the REAL classification [J].
Ascani, S ;
Zinzani, PL ;
Gherlinzoni, F ;
Sabattini, E ;
Briskomatis, A ;
deVivo, A ;
Piccioli, M ;
Orcioni, GF ;
Pieri, F ;
Goldoni, A ;
Piccaluga, PP ;
Zallocco, D ;
Burrelli, R ;
Leoncini, L ;
Falini, B ;
Tura, S ;
Pileri, SA .
ANNALS OF ONCOLOGY, 1997, 8 (06) :583-592
[5]  
Chan WC, 1997, BLOOD, V89, P3909
[6]   DIRECT COMPARISONS OF PERIPHERAL T-CELL LYMPHOMA WITH DIFFUSE B-CELL LYMPHOMA OF COMPARABLE HISTOLOGICAL GRADES - SHOULD PERIPHERAL T-CELL LYMPHOMA BE CONSIDERED SEPARATELY [J].
CHENG, AL ;
CHEN, YC ;
WANG, CH ;
SU, IJ ;
HSIEH, HC ;
CHANG, JY ;
HWANG, WS ;
SU, WC ;
LIU, TW ;
TIEN, HF ;
TSAI, W ;
SHEN, MC ;
LIU, CH .
JOURNAL OF CLINICAL ONCOLOGY, 1989, 7 (06) :725-731
[7]   PERIPHERAL T-CELL LYMPHOMAS HAVE A WORSE PROGNOSIS THAN B-CELL LYMPHOMAS - A PROSPECTIVE-STUDY OF 361 IMMUNOPHENOTYPED PATIENTS TREATED WITH THE LNH-84 REGIMEN [J].
COIFFIER, B ;
BROUSSE, N ;
PEUCHMAUR, M ;
BERGER, F ;
GISSELBRECHT, C ;
BRYON, PA ;
DIEBOLD, J .
ANNALS OF ONCOLOGY, 1990, 1 (01) :45-50
[8]   REPORT OF THE 1ST WORKSHOP ON PROGNOSTIC FACTORS IN LARGE-CELL LYMPHOMAS [J].
COIFFIER, B ;
SHIPP, MA ;
CABANILLAS, F ;
CROWTHER, D ;
ARMITAGE, JO ;
CANELLOS, GP .
ANNALS OF ONCOLOGY, 1991, 2 :213-217
[9]  
COX DR, 1972, J R STAT SOC B, V34, P187
[10]  
GISSELBRECHT C, 1998, IN PRESS BLOOD